๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Firategrast for relapsing remitting multiple sclerosis: a phase 2, randomised, double-blind, placebo-controlled trial

โœ Scribed by David H Miller; Thomas Weber; Richard Grove; Claire Wardell; Joseph Horrigan; Ole Graff; Gillian Atkinson; Pinky Dua; Tarek Yousry; David MacManus; Xavier Montalban

Book ID
114409967
Publisher
The Lancet
Year
2012
Tongue
English
Weight
267 KB
Volume
11
Category
Article
ISSN
1474-4465

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Ocrelizumab in relapsing-remitting multi
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial
โœ Ludwig Kappos; David Li; Peter A Calabresi; Paul O'Connor; Amit Bar-Or; Frederik ๐Ÿ“‚ Article ๐Ÿ“… 2011 ๐Ÿ› The Lancet ๐ŸŒ English โš– 337 KB

## Background: B lymphocytes are implicated in the pathogenesis of multiple sclerosis. we aimed to assess efficacy and safety of two dose regimens of the humanised anti-cd20 monoclonal antibody ocrelizumab in patients with relapsing-remitting multiple sclerosis. ## Methods: We did a multicentre,